Black Diamond Therapeutics, Inc. (BDTX)
| Market Cap | 99.68M -54.8% |
| Revenue (ttm) | n/a |
| Net Income | -42.56M |
| EPS | -0.74 |
| Shares Out | 57.45M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 432,114 |
| Open | 1.650 |
| Previous Close | 1.660 |
| Day's Range | 1.640 - 1.790 |
| 52-Week Range | 1.600 - 4.940 |
| Beta | 3.46 |
| Analysts | Buy |
| Price Target | 10.00 (+476.37%) |
| Est. Earnings | Nov 20, 2026 |
About BDTX
Black Diamond Therapeutics, Inc., a clinical-stage oncology company, focuses on the discovery and development of MasterKey therapies for patients with genetically defined tumors. The company’s lead product candidate is silevertinib, a brain-penetrant epidermal growth factor receptor MasterKey inhibitor, which is in Phase 2 clinical trial for the treatment of epidermal growth factor receptor mutant non-small cell lung cancer, as well as Phase 2 clinical trial to treat glioblastoma. It is also developing BDTX-4933, a brain-penetrant RAF MasterKey... [Read more]
Financial Performance
Financial StatementsAnalyst Summary
According to 8 analysts, the average rating for BDTX stock is "Buy." The 12-month stock price target is $10.0, which is an increase of 476.37% from the latest price.
News
Black Diamond Therapeutics Transcript: H.C. Wainwright 28th Annual Global Investment Conference
Silevertinib shows best-in-class CNS activity and broad EGFR mutation coverage in NSCLC, with a 60% overall response rate and 86% CNS response rate in recent data. An expedited pivotal trial is planned, and a phase II GBM study is underway. Cash reserves support operations through 2028.
Black Diamond Therapeutics to Participate in H.C. Wainwright 28th Annual Global Investment Conference
CAMBRIDGE, Mass., Sept. 02, 2026 (GLOBE NEWSWIRE) -- Black Diamond Therapeutics, Inc. (Nasdaq: BDTX), a clinical-stage oncology company developing MasterKey therapies that target families of oncogenic...
Raymond James keeps Outperform rating on Black Diamond Therapeutics after Q2
Raymond James analyst Sean McCutcheon maintains a “constructive view” around the market opportunity and unmet need in first-line non-classical mutations and notes that silevertinib hit the firm’s bar ...
Black Diamond Therapeutics setup ‘attractive,’ says Jefferies
Jefferies analyst Maury Raycroft views the Q4 setup for Black Diamond Therapeutics (BDTX) as “attractive” as it sees two “key catalysts” ahead – the updated silevertinib first-line longer-term follow-...
Black Diamond Therapeutics reports Q2 EPS (17c), consensus (20c)
“Silevertinib continued to demonstrate robust clinical activity and durable responses in frontline patients with non-classical EGFR-mutant NSCLC, as presented at ASCO in May,” said Mark Velleca, Presi...
Black Diamond Therapeutics Reports Second Quarter 2026 Financial Results and Provides Corporate Update
CAMBRIDGE, Mass., Aug. 05, 2026 (GLOBE NEWSWIRE) -- Black Diamond Therapeutics, Inc. (Nasdaq: BDTX), a clinical-stage oncology company developing MasterKey therapies that target families of oncogenic ...
Black Diamond Therapeutics Quarterly report: Q2 2026
Black Diamond Therapeutics has published its Q2 2026 quarterly earnings report on August 5, 2026.
Black Diamond Therapeutics Earnings release: Q2 2026
Black Diamond Therapeutics released its Q2 2026 earnings on August 5, 2026, summarizing the period's financial results.
Black Diamond Therapeutics Transcript: AGM 2026
The meeting covered director elections, auditor ratification, and advisory votes on executive compensation, all of which were approved by stockholders. No questions were submitted on the official business, and the meeting was adjourned after confirming voting outcomes.
Black Diamond Therapeutics Transcript: Jefferies Global Healthcare Conference 2026
Black Diamond Therapeutics to Participate in Jefferies Global Healthcare Conference
CAMBRIDGE, Mass., May 22, 2026 (GLOBE NEWSWIRE) -- Black Diamond Therapeutics, Inc. (Nasdaq: BDTX), a clinical-stage oncology company developing MasterKey therapies that target families of oncogenic m...
Black Diamond Therapeutics Transcript: Study result
Phase II results show silevertinib achieved a 60% objective response rate and 86% CNS response rate in frontline EGFR NCM non-small cell lung cancer, with a median PFS of 15.2 months and manageable safety profile. No new brain metastases developed during treatment.
Black Diamond Therapeutics Press release: Study result
Black Diamond Therapeutics issued a press release on May 21, 2026, disclosing material business information to investors.
Black Diamond Therapeutics Announces Positive Phase 2 Results for Silevertinib in Frontline NSCLC Patients with EGFR Non-Classical Mutations
CAMBRIDGE, Mass., May 21, 2026 (GLOBE NEWSWIRE) -- Black Diamond Therapeutics, Inc. (Nasdaq: BDTX), a clinical-stage oncology company developing MasterKey therapies that target families of oncogenic m...
Black Diamond Therapeutics Slides: Corporate presentation
Black Diamond Therapeutics has posted slides in relation to its latest quarterly earnings report, which was published on May 21, 2026.
Black Diamond Therapeutics to Host Webcast for Investors Highlighting Updated Results from Phase 2 Trial of Silevertinib in 1L EGFRm NSCLC
Webcast will be held Thursday, May 21, 2026, at 5:30 p.m. ET CAMBRIDGE, Mass.
Black Diamond Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate Update
Oral presentation of silevertinib Phase 2 data in frontline EGFRm NSCLC patients, including preliminary DOR and PFS data, to take place at the 2026 ASCO Annual Meeting First patient dosed in the Phase...
Black Diamond Therapeutics Quarterly report: Q1 2026
Black Diamond Therapeutics has published its Q1 2026 quarterly earnings report on May 7, 2026.
Black Diamond Therapeutics Earnings release: Q1 2026
Black Diamond Therapeutics released its Q1 2026 earnings on May 7, 2026, summarizing the period's financial results.
Black Diamond Therapeutics Proxy statement: Proxy filing
Black Diamond Therapeutics filed a proxy statement on April 29, 2026, providing details for shareholder voting and corporate governance matters.
Black Diamond Therapeutics Proxy statement: Proxy filing
Black Diamond Therapeutics filed a proxy statement on April 29, 2026, providing details for shareholder voting and corporate governance matters.
Black Diamond price target raised to $11 from $10 at H.C. Wainwright
H.C. Wainwright analyst Robert Burns raised the firm’s price target on Black Diamond Therapeutics (BDTX) to $11 from $10 and keeps a Buy rating on the shares. Published first on…
Black Diamond Therapeutics Announces Oral Presentation of Silevertinib Phase 2 Data in Frontline EGFRm NSCLC Patients at the 2026 ASCO Annual Meeting
CAMBRIDGE, Mass., April 21, 2026 (GLOBE NEWSWIRE) -- Black Diamond Therapeutics, Inc. (Nasdaq: BDTX), a clinical-stage oncology company developing MasterKey therapies that target families of oncogenic...
Black Diamond Therapeutics price target raised to $14 from $13 at Wedbush
Wedbush raised the firm’s price target on Black Diamond Therapeutics (BDTX) to $14 from $13 and keeps an Outperform rating on the shares following quarterly results and updates regarding silevertinib…
Black Diamond Therapeutics reports Q4 EPS (27c), consensus (17c)
“We continue to focus on advancing silevertinib for the treatment of patients with EGFRm NSCLC and EGFR altered GBM,” said Mark Velleca, president and CEO of Black Diamond Therapeutics (BDTX).